✦ LIBER ✦

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study

✍ Scribed by Hillmen, P.; Gribben, J. G.; Follows, G. A.; Milligan, D.; Sayala, H. A.; Moreton, P.; Oscier, D. G.; Dearden, C. E.; Kennedy, D. B.; Pettitt, A. R.; Nathwani, A.; Varghese, A.; Cohen, D.; Rawstron, A.; Oertel, S.; Pocock, C. F. E.

Book ID: 127326629
Publisher: American Society of Clinical Oncology
Year: 2014
Tongue: English
Weight: 141 KB
Volume: 32
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2013.49.6547

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

5.40 Rituximab Maintenance in Patients w

5.40 Rituximab Maintenance in Patients with Chronic Lymphocytic Leukemia after First-Line Treatment with Rituximab plus Fludarabine, Cyclophosphamide, and Mitoxantrone: Final Results of a Multicenter Phase II Trial on Behalf of the Spanish CLL Study Group (GELLC)

✍ Francesc Bosch; Pau Abrisqueta; Neus Villamor; María José Terol; Eva González-Ba 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 250 KB

Single-Agent Rituximab as First-Line and

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network

✍ Hainsworth, J. D. 📂 Article 📅 2003 🏛 American Society of Clinical Oncology 🌐 English ⚖ 73 KB